Cargando…

Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases

SIMPLE SUMMARY: Standard treatment protocol for PIPAC consists of three procedures and completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. This retrospective multicentric cohort study included all...

Descripción completa

Detalles Bibliográficos
Autores principales: Balmer, Aurélie, Clerc, Daniel, Toussaint, Laura, Sgarbura, Olivia, Taïbi, Abdelkader, Hübner, Martin, Teixeira Farinha, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139612/
https://www.ncbi.nlm.nih.gov/pubmed/35626160
http://dx.doi.org/10.3390/cancers14102557
_version_ 1784714900054999040
author Balmer, Aurélie
Clerc, Daniel
Toussaint, Laura
Sgarbura, Olivia
Taïbi, Abdelkader
Hübner, Martin
Teixeira Farinha, Hugo
author_facet Balmer, Aurélie
Clerc, Daniel
Toussaint, Laura
Sgarbura, Olivia
Taïbi, Abdelkader
Hübner, Martin
Teixeira Farinha, Hugo
author_sort Balmer, Aurélie
collection PubMed
description SIMPLE SUMMARY: Standard treatment protocol for PIPAC consists of three procedures and completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. This retrospective multicentric cohort study included all patients with peritoneal metastases undergoing PIPAC at three PIPAC expert centers. Overall, 183 patients had 517 PIPACs. Bimodal treatment was found as an independent predictive factor for completing the three procedures (OR = 4.202, 95%CI [1.813, 10.630], p < 0.001), as well as prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037). In conclusion, the absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy. ABSTRACT: Background: The standard treatment protocol for PIPAC consists of three procedures. Completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. Methods: Retrospective multicentric cohort study of patients with peritoneal metastases undergoing PIPAC in three PIPAC expert centers. Per protocol (PP) treatment was defined as patients receiving ≥3 PIPACs and was compared to patients receiving <3. Results: Overall, 183 patients had 517 PIPACs. The main reasons for stopping PIPAC were disease progression in 50% patients, bowel obstruction in 15%, patient’s refusal to pursue in 10%, conversion to cytoreductive surgery in 7%, and medical reasons in 8%. Overall, 95 patients (52%) had PP treatment. The PP median OS was 17 vs. 7 months, p = 0.001. PP patients had r ascites (410 ± 100 mL vs. 960 ± 188 mL, p = 0.001), no prior history of bowel obstruction (12% vs. 24%, p = 0.028), and more bimodal treatment (39% vs. 13%, p < 0.001). After multiple regression, bimodal treatment was found as an independent predictive factor for completing PP (OR = 4.202, 95%CI [1.813, 10.630], p < 0.001), along with prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037). Conclusion: The absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy.
format Online
Article
Text
id pubmed-9139612
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91396122022-05-28 Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases Balmer, Aurélie Clerc, Daniel Toussaint, Laura Sgarbura, Olivia Taïbi, Abdelkader Hübner, Martin Teixeira Farinha, Hugo Cancers (Basel) Article SIMPLE SUMMARY: Standard treatment protocol for PIPAC consists of three procedures and completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. This retrospective multicentric cohort study included all patients with peritoneal metastases undergoing PIPAC at three PIPAC expert centers. Overall, 183 patients had 517 PIPACs. Bimodal treatment was found as an independent predictive factor for completing the three procedures (OR = 4.202, 95%CI [1.813, 10.630], p < 0.001), as well as prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037). In conclusion, the absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy. ABSTRACT: Background: The standard treatment protocol for PIPAC consists of three procedures. Completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. Methods: Retrospective multicentric cohort study of patients with peritoneal metastases undergoing PIPAC in three PIPAC expert centers. Per protocol (PP) treatment was defined as patients receiving ≥3 PIPACs and was compared to patients receiving <3. Results: Overall, 183 patients had 517 PIPACs. The main reasons for stopping PIPAC were disease progression in 50% patients, bowel obstruction in 15%, patient’s refusal to pursue in 10%, conversion to cytoreductive surgery in 7%, and medical reasons in 8%. Overall, 95 patients (52%) had PP treatment. The PP median OS was 17 vs. 7 months, p = 0.001. PP patients had r ascites (410 ± 100 mL vs. 960 ± 188 mL, p = 0.001), no prior history of bowel obstruction (12% vs. 24%, p = 0.028), and more bimodal treatment (39% vs. 13%, p < 0.001). After multiple regression, bimodal treatment was found as an independent predictive factor for completing PP (OR = 4.202, 95%CI [1.813, 10.630], p < 0.001), along with prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037). Conclusion: The absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy. MDPI 2022-05-23 /pmc/articles/PMC9139612/ /pubmed/35626160 http://dx.doi.org/10.3390/cancers14102557 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Balmer, Aurélie
Clerc, Daniel
Toussaint, Laura
Sgarbura, Olivia
Taïbi, Abdelkader
Hübner, Martin
Teixeira Farinha, Hugo
Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases
title Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases
title_full Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases
title_fullStr Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases
title_full_unstemmed Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases
title_short Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases
title_sort selection criteria for pressurized intraperitoneal aerosol chemotherapy (pipac) treatment in patients with peritoneal metastases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139612/
https://www.ncbi.nlm.nih.gov/pubmed/35626160
http://dx.doi.org/10.3390/cancers14102557
work_keys_str_mv AT balmeraurelie selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases
AT clercdaniel selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases
AT toussaintlaura selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases
AT sgarburaolivia selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases
AT taibiabdelkader selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases
AT hubnermartin selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases
AT teixeirafarinhahugo selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases